Phase 1 N=12 Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants
Healthy
Primary: Renal Clearance (CLr) of Metformin — 32.18; 33.33 litre per hour (L/hr)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=46 A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment
Healthy
Primary: Skin Irritation Score — 0; 0; 339; 15 Normalized cumulative irritation score — p=<0.0001
Phase 1 N=61 A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers
Healthy
Primary: Observed Photoallergy (Photosensitization): Number of Skin Sites by Maximum Total Irritation Score — 10; 3; 1; 0 Number of affected skin sites
Phase 1 N=34 Remote Limb Ischemic Conditioning to Enhance Learning and Muscle Strength in Healthy Young Adults
Healthy, Young Adults
Primary: One-repetition Maximum of Wrist Extensors — 22.6; 23.7; 32.0; 29.9 lbs — p=0.002
Phase 1 N=16 A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants
Healthy Volunteer
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 — 2877; 6250; 2444; 5460 nanogram per milliliter (ng/mL)
Phase 1 N=56 A Study of Lasmiditan on the Heart in Healthy Participants
Healthy
Primary: Change From Time Matched Baseline in Mean Fridericia-Corrected QT (QTcF) Values of Lasmiditan and Moxifloxacin — -8.90; -9.27; -5.49; 1.90 milliseconds
Phase 1 N=24 Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Maximum Plasma Drug Concentration (Cmax) Occurred at the Time of Maximum Observed Concentration Sampled During a Dosing Interval (Tmax) of Plasma Dextroamphetamine…
Phase 1 N=40 A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants
Healthy Volunteers
Primary: Part 1: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 2; 2; 3; 4 Participants
Phase 1 N=40 Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)
Healthy Volunteers
Primary: Assessment of Safety Based Primarily on the Frequency and Nature of Adverse Events, Clinical Laboratory Assessments (Chemistry, Hematology, and Urinalysis), Physical…
Phase 1 N=30 Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules
Healthy Volunteers
Primary: Concentration as Measured by Maximum Observed Plasma Concentration (Cmax) — 77.4; 99.3 ng/mL
Phase 1 N=16 Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model
Norovirus Infection
Primary: Frequency of Norovirus Gastroenteritis (NVG) — 5; 4 Participants
Phase 1 N=12 Safety Evaluation of Advantage Anti-Caries Varnish
Dental Caries
Primary: Soft Tissue — 0 Participants
Phase 1 N=5 Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Lung Metastasis
Primary: Feasibility to Perform Interstitial-Photodynamic Therapy (i-PDT) Into Tumor — 3; 0; 1; 1 Participants
Phase 1 N=32 Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
Non-Hodgkin's Lymphoma · Acute Leukemia in Remission · Chronic Myeloid Leukemia
Primary: Incidence of Grade II-IV Acute Graft vs. Host Disease (GVHD) — 18.8 percentage of participants
Phase 1 N=64 A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006
Insomnia
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) — 7; 1; 0; 1 Participants